Cerenome, Inc.
CNSYHealthcare|Medical - Pharmaceuticals|US
$0.64
-0.03 (-4.06%)
DCF Value
$2.01
Tangible Book / Share
$0.71
Cash / Share
$1.27
Next Earnings Report
Feb 25, 2027
EPS est. -$0.86 · Revenue est. $2.0M
Upcoming Data Readouts (4)
Apr 2027
Est. completion
P1P2Glioma
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
NCT01906385n=55
Jul 2027
Est. completion
P1P2Leptomeningeal Metastasis
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
NCT07098806n=24
Mar 2028
Est. completion
P1Ependymoma
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
NCT07061626n=56
Mar 2028
Est. completion
P1Glioma
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
NCT05460507n=40
Recent Press Releases
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
Nov 4, 2026 · GlobeNewsWire
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
Oct 29, 2026 · GlobeNewsWire
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
Oct 27, 2026 · GlobeNewsWire
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
Oct 21, 2026 · GlobeNewsWire
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
Oct 8, 2026 · GlobeNewsWire
Cerenome Launches CNSide® CSF Molecular Profile Tests
Oct 6, 2026 · GlobeNewsWire
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Sep 30, 2026 · GlobeNewsWire
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
Sep 25, 2026 · GlobeNewsWire
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
Sep 22, 2026 · GlobeNewsWire
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
Sep 16, 2026 · GlobeNewsWire